                                                                                 British Journal Cancer (2010) 103, 975 â€“ 986
                                                                                 & 2010 Cancer Research UK rights reserved 0007 â€“ 0920/10
                                                                                 www.bjcancer.com




Selective cyclooxygenase-2 silencing mediated engineered
E. coli RNA interference induces anti-tumour effects human
colon cancer cells
  
  
  
     Strillacci*,1, C Griffoni1, G Lazzarini1,2, MC Valerii1,2, S Di Molfetta1, F Rizzello2, M Campieri2, MP Moyer3,
  
     V Tomasi1 E Spisni*,1
  
     1
      Department Experimental Biology, University Bologna, Selmi 3, Bologna 40126, Italy; 2Department Clinical Medicine, St Orsola-Malpighi
  
     Hospital, Massarenti 9, Bologna 40138, Italy; 3INCELL Corporation, Cimarron Path 12734, San Antonio, TX 78249, USA
  
  
  




                                                                                                                                                           Translational Therapeutics
  
  
  
     BACKGROUND: Cyclooxygenase-2 (COX-2) overexpression strongly associated colorectal tumourigenesis.   
     demonstrated chronic use non-steroidal anti-inflammatory drugs (COX inhibitors) partially protects patients   
     colorectal cancer (CRC) development progression induces severe cardiovascular effects. New strategies selective
  
     COX-2 blockade required.
  
     METHODS: developed improved technique, based RNA interference (RNAi), gain selective COX-2 silencing CRC
  
     cells tumour-dependent expression anti-COX-2 short-hairpin RNA (shCOX-2). Anti-COX-2 shRNA-expressing vectors
  
     delivered CRC cells  vitro) colon tissues (ex vivo) using engineered Escherichia coli strains, capable invading tumour
  
     cells (InvColi).
  
     RESULTS: highly tumour-dependent shCOX-2 expression significant COX-2 silencing observed CRC cells following
  
     InvColi strain infection. Cyclooxygenase-2 silencing associated strong reduction proliferative invasive behaviour
  
     tumour cells. demonstrated pivotal role COX-2 overexpression survival CRC cells bacterial infection.
  
      COX-2 silencing achieved ex vivo infecting colon tissue samples InvColi strains, leading anti-inflammatory
  
     anti-tumour effects.
  
     CONCLUSION: RNAi/InvColi-mediated approach offers promising tool highly selective COX-2 blockade vitro vivo.
  
     British Journal Cancer (2010) 103, 975 â€“ 986. doi:10.1038/sj.bjc.6605859 www.bjcancer.com
  
     Published online 17 August 2010
  
     & 2010 Cancer Research UK
  
  
  
     Keywords: COX-2; CRC; RNAi; E. coli


Colorectal cancer (CRC) represents common                         80  adenocarcinomas (Eberhart et al, 1994; Sano et al,
tumour humans second leading cause tumour-                         1995), overexpression strongly associated
related death Western countries. Europe, 44 00 000 new                     colon tumourigenesis vitro murine models
cases 42 00 000 deaths year estimated (Ferlay et al,                 (DuBois et al, 1996; Oshima et al, 1996; Williams et al, 1996). 2007). mortality rate CRC dramatically increases                     commonly accepted COX-2 contribute CRC develop-
tumour cells invade primary tissue generate lymph nodal                  ment progression mechanisms involving stimula- liver metastases. Owing high incidence mortality                  tion angiogenesis (Spisni Tomasi, 1997; iguez et al, 2003),
rate, CRC great scientific community.                     inhibition apoptosis (Tsujii DuBois, 1995)    decades, demonstrated                  increase cell migration/invasiveness (Yamauchi et al, 2002;
chronic use non-steroidal anti-inflammatory drugs (NSAIDs),                   Strillacci et al, 2006).
blocking isoforms 1 2 cyclooxygenase (COX) enzyme,                       Celecoxib rofecoxib NSAIDs marketed confers 40 â€“ 50  reduction incidence CRC (Phillips et al,            selective COX-2 inhibitors used clinical
2002; Thun et al, 2002; Higuchi et al, 2003; Sandler et al, 2003).               trials test efficacy prevention treatment
Cyclooxygenase key enzyme metabolism arachidonate                 CRC. Unfortunately, celecoxib  particularly, rofecoxib regulates synthesis prostaglandins (H2, D2, E2, F2a, I2)              shown significantly increase risk adverse tromboxanes (TXA2 TXB2), having important roles                     cardiovascular events myocardial infarction treated patients cellular mediators. Cyclooxygenase-2 represents product                (Bresalier et al, 2005; Solomon et al, 2005).  Cox-2 inducible gene. overexpressed 40  adenomas                 cardiovascular toxicity rofecoxib increased                                                                                  capability directly inhibit prostacyclin synthase activity,                                                                                  demonstrated group (Griffoni et al, 2007). *Correspondence: Dr Strillacci; E-mail: antonio.strillacci@unibo        celecoxib marketed, rofecoxib withdrawn Dr E Spisni; E-mail: enzo.spisni@unibo                                        worldwide market Merck September 2004.
Received 16 April 2010; revised 21 July 2010; accepted 22 July 2010;                RNA interference (RNAi) rapidly innovative published online 17 August 2010                                                  elective tool gene silencing post-transcriptional level.
                                                                 RNAi COX-2 silencing CRC cells
                                                                                        Strillacci et al
                             976
                                   RNAi-mediated gene silencing achieved using small                  informed consent participate study, approved
                                   interfering RNA (siRNA) short-hairpin RNA (shRNA)                   local ethical committee.
                                   precursor molecules. synthetic siRNAs introduced
                                   mammal cells using standard vitro transfection methods,             Plasmids
                                   shRNAs expressed transfecting cells plasmids (Lewis
                                   et al, 2002) viral-based vectors (Brummelkamp et al, 2002).            pSUPER.retro vector (pS), based murine stem
                                   Numerous advantages come shRNA-based RNAi approach:                  cell virus (MSCV) genome, purchased Oligoengine
                                    possibility obtain long-term gene silencing;          (Seattle, WA, USA). pSUPER.retro vector expressing shCOX-2
                                   second, possibility express shRNAs spatial-            RNA pol III H1 promoter control (pSH1) created                                    temporal-specific manner using tissue-specific promoters               described (Strillacci et al, 2006). pSUPER.retro vectors
                                   introducing regulatory elements shRNA promoters.                       expressing shCOX-2 control human Cox-2 promoter
                                      2006, research group demonstrated possible        (pSCOX2) TBE (Tcf-binding element)-based promoter (pSTBE)
                                   stably silence COX-2 protein CRC cell line (HT-29) using         created follows: vectors, RNA pol III transcription
                                   anti-COX-2 shRNA (shCOX-2). HT-29pS(shCOX2) showed                 stop signal substituted SV40 polyA sequence                                    significant impairment malignant behaviour (Strillacci et al,          HindIII SalI restriction sites (SV40 polyA sequence                                    2006) reduced ability survive hypoxic conditions           amplified pSG5 expression plasmid; forward primer:
                                   (Sansone et al, 2009). date, RNAi approaches used         50 -CCCAAGCTTAAATAAAGCAATAGCATCAC-30 ; reverse primer:
                                   efficiently silence COX-2 protein different vitro          50 -TAGAGTCGACCAGACATGATAAGAT-30 , 120 bp product);                                    models  review, Strillacci et al, 2010).                        pSCOX2, H1 promoter (pH1) substituted human
                                      years ago, demonstrated functional gene          Cox-2 promoter sequence (pCOX-2) ApaI BglII
                                   transfer bacteria mammalian cells occur.                    restriction sites (pCOX-2 sequence amplified HCA-7
Translational Therapeutics




                                   particular, engineered Escherichia coli, expressing Inv            genomic DNA; forward primer: 50 -CGGGCCCTGAGCACTACCC
                                   HlyA genes  Yersinia pseudotuberculosis Lysteria                 ATGATA-30 ; reverse primer: 50 -GAAGATCTCCGAGAGAA
                                   monocytogenes, respectively), able invade          CCTTCC-30 , 1254 bp product); pSTBE, pH1 substituted                                    release DNA host cells (Grillot-Courvalin et al, 1998).         TBE-based promoter sequence (pTBE) ApaI BglII
                                   phenomenon demonstrated vivo, observed              restriction sites  pTBE sequence amplified 
                                   invasive E. coli deliver therapeutic genes colonic        FLASH plasmid, kindly provided Dr Hans Clevers, University
                                   mucosa mice (Castagliuolo et al, 2005). Similarly, successful        Hospital, Utrecht, Netherlands; forward primer: 50 -CG
                                   transfer shRNA mammalian cells achieved using non-            GGCCCAAGCTATCAAAGGG-30 ; reverse primer: 50 -CGAGAT
                                   pathogenic E. coli transformed plasmid containing                  CTGGCGCCTCAGCTGGC-30 , 151 bp product). comprehensive
                                   expression cassettes shRNA Inv/HlyA genes. 2006,               scheme pS vectors described shown Figure 1.
                                   Xiang et al (2006) applied new strategy time
                                   (termed â€˜trans-kingdom RNAiâ€™) silence b-1 catenin gene             Transfections
                                   (CTNNB1) human cells vitro vivo.
                                      paper, effective method shCOX-         HCA-7, HT-29, HCT-116, NCM-460, HeLa HEK-293 cells                                    2-expressing vectors delivered CRC cells  vitro)       seeded 6 plates (B7  105 cells  70  confluence.
                                   COX-2-overexpressing colonic tissues (ex vivo), using invasive         24 h, cells transfected pS, pSH1, pSCOX2                                    E. coli strains achieve strong COX-2 silencing mediated           pSTBE vectors using Lipofectamine 2000 transfection reagent
                                   RNAi, coupled anti-tumour effects. strategy prove          (Invitrogen, Carlsbad, CA, USA) according manufacturerâ€™s
                                   suitable vivo application aiming COX-2 inhibition         instructions. 6 h incubation 371C, transfection
                                   CRC prevention.                                                       medium replaced 2 ml complete medium containing
                                                                                                             10  FCS. Cells lysed 48 h transfection real-time PCR
                                                                                                             western blot analyses.
                                   MATERIALS METHODS
                                                                                                             RNA extraction real-time PCR
                                   Cell lines
                                                                                                             Total RNA cultured cells extracted using Eurozol reagent
                                   Human cancer cell lines HCA-7, HT-29, HCT-116, HeLa                   (Celbio, Milan, Italy) according manufacturerâ€™s instructions.
                                   human transformed kidney cell line HEK-293 obtained                  Extracted RNA samples treated DNase remove                                    American Type Culture Collection (Manassas, VA, USA).            genomic DNA contamination using DNA-free kit (Ambion, Austin,
                                   Normal human colon mucosal epithelial cell line NCM-460 (Moyer            TX, USA) reverse transcribed using RevertAid Strand
                                   et al, 1996) obtained licensing agreement INCELL         cDNA Synthesis Kit (Fermentas, Burlington, Ontario, Canada).
                                   Corporation (San Antonio, TX, USA). HT-29pS() HT-               COX-2 b-glucuronidase (GUSB) mRNAs reverse
                                   29pS(shCOX2) cells previously created group,         transcribed using random hexamer primers (Fermentas).                                    described (Strillacci et al, 2006). Cell lines cultured    siCOX-2 reverse transcribed using stem-loop RT â€“ PCR
                                   371C 5  CO2 Dulbeccoâ€™s modified Eagleâ€™s medium                   technique (Chen et al, 2005) using following primer: 50 -G
                                   (DMEM) supplemented 10  heat-inactivated fetal calf serum            TCGTATCCAGTGCAGGGTCCGAGGTATTCGCACTGGATACGAC
                                   (FCS), 2 mM L-glutamine kanamycin 100 mg ml1. FCS               AAATTCC-30 . U6 RNA reverse transcribed using following
                                   DMEM purchased Cambrex BioWhittaker (Charles                primer: 50 -AAAATATGGAACGCTTCACG-30 . COX-2 mRNA
                                   City, IA, USA). NCM-460 cells cultured M3 base            siCOX-2 levels analysed real-time PCR using SYBR
                                   media obtained INCELL Corporation. reagents           supermix (Bio-Rad, Hercules, CA, USA) iCycler (Bio-
                                   purchased Sigma (St Louis, MO, USA).                                 Rad) according manufacturerâ€™s instructions. melting
                                                                                                             curve data collected check PCR specificity. cDNA
                                   Colon tissue culture                                                      sample analysed triplicate. Cyclooxygenase-2 mRNA levels
                                                                                                             normalised GUSB mRNA, siCOX-2 expres-
                                   Fresh colon biopsies collected patients affected acute       sion normalised U6 RNA levels. Relative expressions
                                   ulcerative colitis endoscopy immediately cultured           calculated using formula 22DCt values (DCt Â¼
                                   MegaCell RPMI-1640 medium (Sigma). Patients gave written              CtgeneCthk). Cyclooxygenase-2 primer pair: 50 -CCTGTGCCTGAT

                                   British Journal Cancer (2010) 103(7), 975 â€“ 986                                                                 & 2010 Cancer Research UK
                                                                            RNAi COX-2 silencing CRC cells
                                                                           Strillacci et al
                                                                                                                                                                   977
                                                                                                                                                   â€œAAAAAâ€?
                                                                                                 RNA pol III                                      pol III stop

                                                                 pSâ€“                       pH1                           Stuffer

                                                                           EcoRI Apal                       BgIII                           Hind III Sall

                                                                                                                                       â€œAAAAAâ€?
                                   GFP                                                           RNA pol III                          pol III stop
                       PurR                  PGK
                                                                 pSH1                      pH1                      shCOX2
             Î”3â€™LTR
                                                                           EcoRI Apal                       BgIII               Hind III Sall
                                                    shCOX-2
                             psuper.retro
                                                    cassette                  Î”pH1                         RNA pol II
                Ori
                                                                                                                                                  SV40
                                                Ïˆ                pSCOX-2                      pCOX2                             shCOX2            polyA

                                            5â€™LTR                          EcoRI Apal                                  BgIII                Hind III        Sall
                      AmpR

                                                                              Î”pH1       RNA pol II

                                                                                                                            SV40
                                                                                     pTBE                 shCOX2
                                                                 pSTBE                                                      polyA




                                                                                                                                                                         Translational Therapeutics
                                                                            EcoRI Apal            BgIII              Hind III        Sall
                                                    
Figure 1 Scheme pSUPER.retro vectors. pS : original pSUPER.retro vector, H1 promoter upstream â€˜stufferâ€™ sequence; pSH1: pSUPER.retro
vector shCOX-2 expression controlled H1 promoter; pSCOX2: pSUPER.retro vector shCOX-2 expression controlled human
Cox-2 promoter; pSTBE: pSUPER.retro vector shCOX-2 expression controlled TBE-based promoter (carrying Tcf-binding elements).


GATTGC-30 50 -CTGATGCGTGAAGTGCTG-30 (165 bp pro-                       SDS â€“ PAGE sample buffer boiling, 40 mg denatured proteins
duct); siCOX-2 primer pair: 50 -GCAACTGCTCAACACCG-30                   separated 12  SDS â€“ PAGE transferred 50 -TGCAGGGTCCGAGGTAT-30 (56 bp product); GUSB primer                      nitrocellulose papers. blotting, nitrocellulose papers pair: 50 -TGGTATAAGAAGTATCAGAAGCC-30 50 -GTATC                         incubated specific antibodies. primary antibodies used
TCTCTCGCAAAAGGAAC-30 (297 bp product); U6 primer pair:                     polyclonal anti-COX-2 (Cayman Chemicals, Ann Arbor, MI,
50 -CTTCGGCAGCACATATACT-30 50 -AAAATATGGAACG                           USA) anti-b-actin (Sigma). Secondary antibodies (HRP
CTTCACG-30 (99 bp product).                                                conjugated) purchased Santa Cruz Biotechnology
                                                                           (Santa Cruz, CA, USA). Immunolabelling visualised using
InvColi strains bacterial infection                                    ECL procedure (Amersham Biosciences, Piscataway, NJ, USA).
                                                                           Bands quantified using densitometric image analysis software E. coli (DH5a strain) transformed pGB2-O-              (Quantity  Bio-Rad). Normalisation b-actin
inv-hly plasmid (SmR Ã¾ , kindly provided Dr Catherine Grillot-          expression.
Courvalin, Institut Pasteur, Paris) pSUPER.retro (AmpR Ã¾ )
vectors obtain E. coli invasive strains carrying different    Fluorescence Inv-HlyA-pTBE sequence detection
shCOX-2 expression vectors  InvColi-pSH1, InvColi-
pSCOX2 InvColi-pSTBE) negative control (InvColi-              InvColi pSTBE-infected cells analysed 48 h infection
pS). Selection transformed strains based                using Nikon Eclipse 90i microscope (Nikon, Tokyo, Japan) streptomycin ampicillin resistance. HT-29 HCA-7               detect green fluorescent protein (GFP) expression. total DNA
cell lines infected InvColi strains according             infected cells extracted using phenol/chloroform procedure
following procedure: cells seeded 25 cm2 flasks 50              24 h infection, presence pGB2-O-inv-hly pSTBE
confluence (B3  106 cells) antibiotic-free medium (DMEM);           plasmids confirmed standard PCR technique, followed InvColi strains grown LB medium 371C reach                agarose gel electrophoresis analysis. Inv primer pair: 50 -GCCAA
OD600 B1.00; InvColi bacteria washed twice fresh           TAAGGAGCAGGAGAC-30 50 -CCAAGGAGCCAGCCAATC-30
LB medium, suspended antibiotic-free DMEM added               (225 bp product); HlyA primer pair: 50 -CATTTCACATCGTC
cellsâ€™ media MOI (multiplicity infection) 1:1000; 2 h    CATCTATTTG-30 50 -TTACCGTTCTCCACCATTCC-30 (100 bp incubation 371C 5  CO2, cells washed fresh               product); pTBE sequence primer pair  . PCR
DMEM medium supplemented kanamycin added                   analysis performed E. coli transformed pGB2-
flasks. Cells lysed 48 h infection western blot         O-inv-hly pSTBE plasmids (pre-heated 951C 5 min) real-time PCR analyses. regard colon tissue samples,               purified plasmids 
infection achieved immediately endoscopic resection culturing biopsies InvColi-pS strains MegaCell RPMI-             Cell proliferation viability analysis
1640 medium described  Biopsies lysed supernatants collected 48 h infection western blot,         HT-29 HCA-7 cells infected InvColi strains.
real-time PCR Luminex (Luminex, Austin, TX, USA) analyses.             hours infection (day 0), cells seeded                                                                            12 plates (HT-29: 5  104 cells  HCA-7: 2  104 cells
Western blot                                                               . days 1, 2, 3, 6 8, cells trypsinised, 
                                                                           suspended PBS 1  incubated 10 min 0.4  Trypan
Cultured cells homogenised lysis buffer (50 mM Tris-HCl,           Blue (Sigma). Cells counted haemocytometer pH 7.5, 2 mM EDTA, 100 mM NaCl, 1  Triton X-100, protease                  unstained (viable) stained cells. percentage cell viability
inhibitors mixture). Cell lysates incubated 1 h ice            calculated ((number unstained cells)/(number total
centrifuged 12 000 g collect supernatants. addition         cells))  100.

& 2010 Cancer Research UK                                                                                 British Journal Cancer (2010) 103(7), 975 â€“ 986
                                                                 RNAi COX-2 silencing CRC cells
                                                                                        Strillacci et al
                             978
                                   Cell invasion assay                                                                    RESULTS
                                   Invasion assay performed using Boyden chambers (New                                Selective expression siCOX-2 colon cancer cells
                                   Technologies Group, Milan, Italy) 8-mm pore polycarbonate
                                   membranes (New Technologies Group). Membranes coated                              2006, group demonstrated COX-2 protein                                    Matrigel (Sigma) 40-fold dilution. Assay performed                         efficiently stably downregulated constitutive expression
                                   using fresh DMEM supplemented 10  heat-inactivated                                siRNA targeting COX-2 mRNA (siCOX-2) (Strillacci et al, 2006).
                                   FCS chemoattractant agent. hours InvColi                      HT-29 colon cancer cell line transduced retro-
                                   infection, viable HT-29 HCA-7 cells added upper                      viral vector (pSUPER.retro) containing expressing cassette
                                   chamber high density (3  105 cells) absence                       shCOX-2 (siCOX-2 precursor molecule). pSUPER.
                                   presence phorbol 12-myristate 13-acetate (PMA) 40 nM stimula-                       retro vector, transcription shRNA sequence driven                                    tion incubated 24 h 371C. incubation,                            human H1 promoter RNA pol III (pSH1). H1-driven transcrip-
                                   membranes disassembled non-invasive cells upper                        tion leads constitutive expression shRNA molecules                                    surface membrane wiped cotton swab.                                 different type transduced human cells. improve
                                   invasion index determined counting light                              selectivity siCOX-2 expression, modified expression
                                   microscopy number optical fields (  200 magnification)                     cassette shCOX-2 substituting promoter element.
                                   cells migrated lower membrane, fixing                   particular, created pSCOX2 vector, H1
                                   staining membranes 2  Toluidine Blue.                                         promoter (pH1) substituted human Cox-2 promoter
                                                                                                                          (pCOX-2), pSTBE vector, pH1 substituted                                                                                                                           promoter containing TBEs (pTBEs), derived TOPFLASH
                                   Cytokines, chemokines, growth factors PGE2 detection                               plasmid (largely used luciferase assays). cases, shCOX-
Translational Therapeutics




                                   Simultaneous detection 29 extracellular factors released                         2 transcription driven RNA pol II needs polyA stop
                                   treated colon tissue samples performed using Luminex                               signal  introduced pS-modified vectors,
                                   technology based multiplexed bead immunoassay. assay,                        downstream shCOX-2 sequence) (Figure 1). Using                                    cell media samples concentrated 10 times using Microcon                           approach, shCOX-2 expression dependent COX-2
                                   spin devices (YM3, Millipore, Billerica, MA, USA) subse-                           Wnt/b-catenin cellular pathways, highly activated                                    quently suspended Bio-Plex (Bio-Rad) assay buffer.                           CRC cells. fact, known CRC cells overexpress                                    levels 27 cytokines, chemokines growth factors  1b,                          COX-2 protein phenomenon depends transcriptional
                                   1ra, 2, 4, 5, 6, 7, 8, 9, 10, 12(p70),                   (Yamamoto et al, 1995; Duque et al, 2005; Wu et al, 2005; Kaidi
                                   13, 15, 17, PDGF-bb, bFGF, G-CSF, GM-CSF, VEGF, TNFa,                         et al, 2006) post-transcriptional regulation (Dixon et al, 2001;
                                   IFNg, IP-10, Eotaxin, MCP-1, MIP-1a, MIP-1b, Rantes)                              Strillacci et al, 2009). hand, b-catenin preferentially
                                   measured using human ultrasensitive cytokine 27-plex antibody                      localised plasma membrane normal colonocytes                                    bead kit (Bio-Rad). 1a level measured using Milliplex                       promotes cellular adhesion, linking E-cadherin cytoskeleton.
                                   Map kit (Millipore), PGE2 levels measured using                       CRC cells, consequence mutations (Morin et al, 1997)
                                   Luminex Prostaglandin E2 Kit (Cayman Chemicals). assays                       cellular stimuli (Brabletz et al, 2001; Castellone et al,
                                   performed 96 filter plates, manufacturersâ€™                          2005), b-catenin frequently translocates nucleus                                    instructions. Concentration values estimated using standard                     promotes transcription genes involved cell proliferation,
                                   curve fifth-order polynomial equation expressed                      migration, survival, angiogenesis stemness (Brabletz et al,
                                   ng ml1 log (pg ml1), adjusting dilution factor                      2005). nucleus, b-catenin associates transcriptional
                                   (Bio-Plex Manager software 5.0, Bio-Plex). intra-assay CV,                         complex Tcf-4/Lef-1 (T-cell factor 4/lymphoid enhancer factor 1)
                                   including ultrafiltration immunoassay, averaged 20 .                               binds DNA TBE promoter sequences. Figure 2 shows
                                                                                                                          expression levels siCOX-2 different human cell
                                                                                                                          lines transiently transfected pS  vector, negative
                                   Statistical analysis
                                                                                                                          control), pSH1, pSCOX2 pSTBE vectors. transfecting CRC
                                   Data expressed meanÂ±s.e.m. independent                                cell lines pSCOX2 pSTBE vectors, possible gain                                    experiments. Analysis variance used assess statistical                   highly selective expression siCOX-2. fact, HT-29                                    significance differences. Differences considered                           HCA-7 colon cancer cells, siCOX-2 expression driven pCOX-2
                                   statistically significant Po0.01.                                                   pTBE promoters resulted higher siCOX-2



                                                                                                  3.5
                                                                 siCOX-2/U6 relative expression




                                                                                                   3     HCA-7                                    *
                                                                                                         HT-29
                                                                                                  2.5    HCT-116
                                                                                                   2     NCM-460              *                       *
                                                                                                         HeLa                                              *
                                                                                                  1.5                             *
                                                                                                         HEK-293
                                                                                                   1

                                                                                                  0.5

                                                                                                   0
                                                                                                        pSâ€“        pSH1           pSCOX-2                 pSTBE
                                   Figure 2 Selective expression siCOX-2 CRC cells. human cell lines transfected pS vectors, siCOX-2 expression evaluated                                    real-time PCR (48 h transfection) normalised U6 RNA expression. cell line, relative expression siCOX-2 refers                                    pSH1-transfected sample. Data represent meanÂ±s.e.m. independent experiments. *Po0.01.


                                   British Journal Cancer (2010) 103(7), 975 â€“ 986                                                                                & 2010 Cancer Research UK
                                                                                                               RNAi COX-2 silencing CRC cells
                                                                                                              Strillacci et al
                                                                                                                                                                                                               979
expression driven pH1 promoter. expected, HCT-                                               used InvColi-pSTBE. pSTBE vector, pS vectors
116 colon cancer cell line  does express COX-2                                                   described  carries GFP reporter gene. HT-29 protein), did record significant expression siCOX-2                                               HCA-7 cells infected InvColi-pSTBE started express GFP
driven pCOX-2, siCOX-2 expression driven pTBE                                                   protein 48 h infection (Figure 3A B). B90  infection/ slightly higher pH1. contrary, NCM-460                                                     invasion efficiency estimated cell lines. 
(normal epithelial colon cells), HeLa (human cervix carcinoma                                                 soon infection, possible detect inside cells, cells) HEK-293 (human transformed kidney cell line) cells,                                                PCR analysis, presence Inv-HlyA pTBE sequences,
siCOX-2 expression driven pCOX-2 pTBE resulted                                                   carried pGB2-O-inv-hly plasmid pSTBE vector, low, compared pH1-driven siCOX-2 expression.                                                     respectively (Figure 3C).
                                                                                                                 Using InvColi-mediated RNAi approach, achieved high
                                                                                                              COX-2 silencing CRC cell lines. fact, 48 h infection InvColi infection induces COX-2 silencing CRC cell lines significantly reduces PGE2 synthesis release                                                          invasive InvColi strains transformed shCOX-2-expressing vectors
                                                                                                              (InvColi-pSH1, InvColi-pSCOX2 InvColi-pSTBE), started 1998, Grillot-Courvalin et al (1998) showed engineered                                             observe significant reduction COX-2 protein mRNA levels E. coli strain, expressing heterologous Inv HlyA genes,                                               HT-29 HCA-7 cells (Figure 3D E). Interestingly, COX-2
able infect/invade mammalian cells release DNA host                                               silencing InvColi-pSTBE effective silencing
cells. basis approach, developed strategy                                              obtained InvColi-pS (negative control) InvColi-pSH1/COX2
induce RNAi-mediated COX-2 silencing HT-29 HCA-7                                                    bacteria. likely, stronger COX-2 silencing obtained colon cancer cell lines. Bacterial LPS known induce COX-2                                               InvColi-pSTBE dependent higher siCOX-2 expression,
expression human cells (Hla Neilson, 1992).                                              detected HT-29 HCA-7 cells (Figure 3D E).




                                                                                                                                                                                                                     Translational Therapeutics
tested bacterial infection CRC cells using InvColi-pS                                             Silencing results highly comparable obtained â€˜Materials Methodsâ€™ section details InvColi-pS strains)                                            transfection pS vectors HT-29 HCA-7 cells using different MOIs. MOI value 1:1000, did record                                               Lipofectamine 2000 Transfection Reagent (Invitrogen)  Supple- significant COX-2 overexpression presence                                                   mentary Material). recorded significant COX-2 protein
bacterial LPS (data shown). Second, provided evidence                                             silencing 5 days InvColi-pS infection (data shown).
InvColi strains created laboratory able infect                                             interestingly, prolonged COX-2 inhibition associated invade human CRC cells MOI 1:1000. purpose,                                               strong impairment PGE2 production (Figure 4)  previously


                                                                                                                                                                                InvColi-pSTBE
                                                                                                                                        pGB2-                                      infected
                                                                                                                                       -inv-hly pSTBE InvColi-pSTBE                HT-29



                                                                                                       249
                                                                                                       200
                                                                                                       140

                                                                                                                                Inv     +     â€“     â€“     +     â€“       â€“       +       â€“       â€“
                                                                                                                               HlyA     â€“     +     â€“     â€“     +       â€“       â€“       +       â€“
                                                     HT-29                        HCA-7
                                                                                                                               pTBE     â€“     â€“     +     â€“     â€“       +       â€“       â€“       +

                                                      HT-29                   InvColi                                                 HCA-7                       InvColi
                                                                    â€“      H1
                                                                 pS      pS       pSCOX-2 pSTBE                                                     pSâ€“       pSH1 pSCOX-2 pSTBE

                                                COX-2 72 kDa                                                                    COX-2 72 kDa


                                                -actin 42 kDa                                                                  -actin 42 kDa

                                               2.5                                                                             3.5
                                                                                                   *
                                                                 COX-2 protein                                                                    COX-2 protein                             *
                                                                                                                                 3
                                                2                COX-2 mRNA
                         Relative expression




                                                                                                                                                  COX-2 mRNA
                                                                                                         Relative expression




                                                                 siCOX-2               *                                       2.5                siCOX-2
                                               1.5                                                                               2
                                                                                                                                                                            *
                                                1                                                                              1.5
                                                                                 * *           *
                                                                                           *                                     1                                  * *
                                               0.5                                                                                                                                      *
                                                                                                                               0.5
                                                                                                                                                                                    *
                                                0                                                                                0
                                                         pSâ€“      pSH1        pSCOX-2      pSTBE                                        pSâ€“          pSH1         pSCOX-2           pSTBE

                                                                        InvColi                                                                               InvColi

Figure 3 InvColi-pS strains infect CRC cells induce high COX-2 silencing. GFP protein expression evaluated   HT-29 (B) HCA-7,
48 h InvColi- pSTBE infection (bar Â¼ 30 mm). (C) PCR analysis Inv, HlyA pTBE loci performed pGB2-O-inv-hly- pSTBE-purified
plasmids, lysed InvColi-pSTBE bacteria InvColi-pSTBE-infected HT-29 cells. PCR products analysed electrophoresis 2  agarose gel.
COX-2 protein, COX-2 mRNA siCOX-2 levels detected (D) HT-29 (E) HCA-7 cells, 48 h InvColi strain infection, western blot real-time PCR. COX-2 protein, COX-2 mRNA siCOX-2 expression normalised b-actin protein, GUSB (b-glucuronidase) mRNA U6 RNA levels, respectively. Relative expression COX-2 protein, COX-2 mRNA siCOX-2 refers InvColi-pSH1-infected sample. Data represent
meanÂ±s.e.m. independent experiments. *Po0.01.


& 2010 Cancer Research UK                                                                                                                                 British Journal Cancer (2010) 103(7), 975 â€“ 986
                                                                              RNAi COX-2 silencing CRC cells
                                                                                                     Strillacci et al
                             980
                                   demonstrated western blot analysis, strongest inhibitory effect                                                        pathway) (Sledz et al, 2003). Western blot analysis phospho-
                                   obtained InvColi-pSTBE infection.                                                                                     STAT-1(Tyr701) (active form) levels, normalised p85/p91
                                     evaluated COX-2 silencing induced InvColi-                                                                 STAT-1 total protein levels, showed interferon                                    RNAi result target effect depending                                                               response triggered high MOI values (1:100),                                    interferon activation  particular, Jak-STAT                                                                    infection MOI 1:1000 did effect STAT-1
                                                                                                                                                                   phosphorylation (data shown).


                                                                   pS(â€“)                                                                                           COX-2 silencing mediated RNAi InvColi
                                                                                                                                                                   infection impairs proliferation, survival                                                                    pS(H1)                                 HCA-7
                                                                                                                                                                   invasiveness CRC cells
                                                      16           pS(COX2)
                                                                                                                                                                   demonstrated effective COX-2 silencing CRC cells
                                                      14           pS(TBE)                                                                                         mediated InvColi-pS strains, investigated
                                                                                                                                                                   phenotype infected cells. Figure 5 shows data regarding
                                                      12                                                                                                           proliferation viability COX-2-silenced HT-29 (Figure 5A
                                                                                                                                                                   B) HCA-7 (Figure 5C D) cells results high
                                     PGE2 (ng mlâ€“1)




                                                      10                                                                                                           accordance cell lines. InvColi-pSCOX2  particular,
                                                                                                                                                                   InvColi-pSTBE infection induced significant reduction CRC cell
                                                      8                                                                                          *
                                                                                                           *                                                       proliferation viability, despite InvColi-pSH1 infection led
                                                               *                                                              *                                    slight reduction. COX-2 overexpression involved
                                                      6                         *
                                                                                                                                                                   malignant behaviour invasiveness CRC cells, Translational Therapeutics




                                                                                   *                           *                   *                 *
                                                                                                                                                                   analysed effect specific COX-2 silencing mediated                                                       4
                                                                                                                                                                   InvColi-RNAi HT-29 HCA-7 cells performing cell
                                                                                                               *                  *                  *             invasion assay, 48 h InvColi infection. invasion index
                                                      2
                                                                                                                                                                   cell lines significantly reduced COX-2 silen-
                                                      0                                                                                                            cing (Figure 6A B). HT-29 did record
                                                           1               2                               3                  4                  5                 significant difference effectiveness                                                                                                           Days                                                     InvColi-pSH1, InvColi-pSCOX2 InvColi-pSTBE, HCA-7
                                                                                                                                                                   InvColi-pSCOX2 InvColi-pSTBE, infection induced stronger
                                   Figure 4 Effect COX-2 silencing mediated InvColi-pS PGE2                                                               reduction invasion index respect InvColi-pSH1.                                    production release. Levels PGE2 quantified conditioned                                                           impairment invasive behaviour CRC cells RNAi-
                                   media derived InvColi-pS-infected HCA-7 cells, 5 days                                    infection. (E): cells infected InvColi-pS; (â€™): cells infected                                                       mediated COX-2 silencing confirmed stimulation
                                   InvColi-pSH1; (m): cells infected InvColi-pSCOX2; (K): cells infected                                                PMA, known induce COX-2 expression (Crofford
                                   InvColi-pSTBE. Analysis carried Luminex-based multiplexed bead                                                     et al, 1994) promote cancer cell invasion (Han et al, 2000)
                                   immunoassay. Concentration values expressed ng ml1 represent                                                        (Figure 6A B). findings line pre-
                                   meanÂ±CV independent measurements, normalised considering                                                           vious work demonstrated stable COX-2
                                   total protein extracted tissue sample. *Po0.01.                                                                downregulation HT-29 cells, mediated pH1-driven shCOX-2


                                                                                                                                  HT-29                                                               HT-29
                                                                                                    450                                                                          100
                                                                                                    400             pS(â€“)                                                         90
                                                                            Cell number (x103)




                                                                                                    350             pS(H1)
                                                                                                                                                             *                    80
                                                                                                                                                                 Viability ( )




                                                                                                    300             pS(COX2)                                                                      *                  *               *
                                                                                                                                                                                                  *       *                  *
                                                                                                    250             pS(TBE)                                                       70                                                 *
                                                                                                                                                             *                                            *          *
                                                                                                    200                                                                           60                                         *
                                                                                                                                                     *       *                             pS(â€“)                     *
                                                                                                    150                                                                                    pS(H1)                            *
                                                                                                                                                                                  50
                                                                                                    100                                              *                                     pS(COX2)
                                                                                                                                             *       *                            40
                                                                                                     50                                                                                    pS(TBE)
                                                                                                                                             *
                                                                                                      0                                                                           30
                                                                                                           0         1        2          3       6       8                             0      1       2          3       6       8
                                                                                                                                  Days                                                                    Days
                                                                                                                                  HCA-7                                                               HCA-7
                                                                                                    110                                                                          100
                                                                                                    100            pS(â€“)
                                                                                                                                                                                 90
                                                                                                     90            pS(H1)
                                                                               Cell number (x103)




                                                                                                                   pS(COX2)                                                      80
                                                                                                     80                                                                                        *          *
                                                                                                                                                                 Viability ( )




                                                                                                                                                                                                                     *       *
                                                                                                     70            pS(TBE)                                                       70
                                                                                                                                                                                              *           *
                                                                                                     60                                                      *                   60                                              *
                                                                                                                                                                                                      *              *
                                                                                                     50                                                      *                             pS(â€“)                     *       *    *
                                                                                                                                                     *                           50
                                                                                                     40                                   *                                                pS(H1)                            *
                                                                                                                                  *       *                                      40
                                                                                                     30                                              *                                     pS(COX2)
                                                                                                     20                           *                                              30        pS(TBE)
                                                                                                     10                                                                          20
                                                                                                           0         1        2          3       6       8                             0     1        2          3       6       8
                                                                                                                                  Days                                                                    Days

                                   Figure 5 Effect COX-2 silencing mediated InvColi-pS CRC cell proliferation viability. Cell number cell viability evaluated   B)
                                   infected HT-29 (C, D) HCA-7 cells, respectively. (E): cells infected InvColi-pS; (â€™): cells infected InvColi-pSH1; (m): cells infected                                    InvColi-pSCOX2; (K): cells infected InvColi-pSTBE. Viability evaluated using Trypan Blue exclusion assay quantified ((number                                    unstained cells)/(number total cells))  100. Data represent meanÂ±s.e.m. independent experiments. *Po0.01.


                                   British Journal Cancer (2010) 103(7), 975 â€“ 986                                                                                                                                                    & 2010 Cancer Research UK
                                                                                                                       RNAi COX-2 silencing CRC cells
                                                                                                                      Strillacci et al
                                                                                                                                                                                                           981
                                                                             HT-29                                                                HCA-7
                                                        2.25                                                                       2
                                                          2                                                                      1.75                             PMA â€“




                              Relative invasion index




                                                                                                       Relative invasion index
                                                                                           PMA â€“
                                                        1.75                                                                      1.5                             PMA +
                                                                                           PMA +
                                                         1.5
                                                                                                                                 1.25
                                                        1.25
                                                                                                                                   1              *
                                                          1              *
                                                                                                                                 0.75
                                                        0.75                           *                                                      *
                                                                                                   *                                                          *
                                                         0.5                       *                                              0.5
                                                                     *                        *                                                                               *
                                                                                                                                 0.25                     *               *
                                                        0.25
                                                          0                                                                        0
                                                               pSâ€“   pSH1      pSCOX-2       pSTBE                                      pSâ€“   pSH1      pSCOX-2       pSTBE

                                                                         InvColi                                                                  InvColi

Figure 6 Effect COX-2 silencing mediated InvColi-pS CRC cell invasiveness. Invasion index evaluated   HT-29 (B) HCA-7 cells,
48 h InvColi strain infection. invasion assay performed using Boyden chambers 8-mm polycarbonate membranes coated Matrigel
(40-fold dilution). Samples tested absence (dark bars) presence (light bars) PMA 40 nM. Relative invasion index refers HT-29 HCA-7 cells infected InvColi-pS, treated PMA. Data represent meanÂ±s.e.m. independent experiments. *Po0.01.




                                                                                                                                                                                                                 Translational Therapeutics
expression, induces significant impairment malignant                                                             analysed 48 h infection biopsies InvColi-pS
behaviour HT-29 cells (Strillacci et al, 2006).                                                                    strains (MOI 1:1000, 6 h incubation). shown Figure 9A,
                                                                                                                      negative controls (untreated sample sample infected                                                                                                                       InvColi-pS) characterised COX-2 expression, ex-
CRC cell survival bacterial infection depends                                                                   pected. significant COX-2 protein/mRNA reduction siCOX-2 COX-2 overexpression                                                                                               expression recorded samples infected InvColi-pSH1,
                                                                                                                      InvColi-pSCOX2 InvColi-pSTBE, compared negative  known COX-2 key role colon cancer progression                                                     trols. importantly, InvColi-pSTBE infection strongest survival colon cancer cells. Recently, demonstrated                                                    effect, confirming vitro data  . COX-2/CA-IX (carbonic anhydrase IX) interplay controls CRC                                                          evaluated effect COX-2 silencing colon tissues cell survival hypoxic conditions (Sansone et al, 2009).                                                         analysing levels PGE2, cytokines, chemokines growth  aimed demonstrate COX-2 overexpression                                                          factors present conditioned media 48 h infection. required survival CRC cells infection                                                     analysis, tissue samples infected InvColi-pS
invasive E. coli strains. previously demonstrated                                                          (negative control) InvColi-pSTBE  showed (Strillacci et al, 2006), COX-2 stable silencing mediated                                                          effective COX-2 silencing) taken consideration retroviral transduction did affect proliferation survival                                                     data collected shown Figure 9B C. expected, COX-2 HT-29 cells. fact, did record difference                                                      protein silencing mediated InvColi-pSTBE led strong
proliferation rate HT-29pS() (negative control) HT-                                                      decrease PGE2 secretion.  media derived 29pS(shCOX2)  COX-2 stably downregulated).                                                       InvColi-pSTBE-infected cells, significant decrease prolonged infection invasive InvColi-pS (MOI 1:100,                                                     1a, 1b, 6, 8, 12(p70), 17, PDGF-bb, bFGF, VEGF,
6 h incubation, day 0), observed significant difference cell                                                  IP-10, MCP-1 MIP-1b, observed marked increase
proliferation cell viability HT-29pS() HT-                                                           1ra, 2, 15, TNFa Eotaxin. Levels 4, 5 29pS(shCOX2) cells (Figure 7A B). MOI 1:100, bacterial                                                        10 detectable. Interestingly, COX-2 silencing led infection rapidly induced COX-2 overexpression HT-29pS()                                                          strong decrease secretion pro-inflammatory cytokines
cells (days 1 â€“ 4), probably higher presence LPS                                                   1a/b (Liu et al, 2003; Matsuo et al, 2009), 6 (Becker
(Hla Neilson, 1992), did observe phenomenon                                                       et al, 2005) 8 (Brew et al, 2000), pro-angiogenic HT-29pS(shCOX2) cells (Figure 7C). lack high COX-2                                                         growth factors PDGF-bb (Hsu et al, 1995), bFGF (Galzie
protein levels infected HT-29pS(shCOX2) cells led significant                                                et al, 1997) VEGF (Takahashi et al, 1995). Furthermore, reduction cell proliferation viability. confirm                                                 increased secretion anti-inflammatory cytokines,
important role COX-2 protein CRC cell survival,                                                          1ra (Konishi et al, 2005), cytokines anti-
performed InvColi-pS infection HCT-116 cells, CRC cell line                                                      tumour effect, 2 (Caporale et al, 2007) 15 (Zhang expressing COX-2 protein. expected, COX-2 protein                                                      et al, 2009). Similarly, TNFa increased secretion exert mRNA levels detectable HCT-116 cells 6 h                                                            anti-tumour effect colon cells, role CRC infection InvColi-pS strains MOI 1:100 (data shown).                                                      controversial (Koshiji et al, 1998; Popivanova et al, 2008).  Importantly, absence COX-2 overexpression infected                                                          global analysis ex vivo data, results clear InvColi-
HCT-116 cells led dramatic decrease cell proliferation                                                    mediated RNAi induced COX-2 silencing exerted anti-
viability (Figure 8A B), HT-29pS(shCOX2) cells.                                                      inflammatory anti-tumour effect colon cells.  infected HCT-116 cells showed reduced ability invade
Matrigel-coated filters (Figure 8C).
                                                                                                                      DISCUSSION
COX-2 silencing mediated InvColi strains colon
tissue samples                                                                                                        decades, large body experimental evidence                                                                                                                       ascribed COX-2 enzyme important role colorectal evaluated efficacy COX-2 silencing ex vivo using                                                            tumourigenesis. Cyclooxygenase-2 overexpressed colon
InvColi-based RNAi fresh colon tissue samples.                                                             tumour tissues (Eberhart et al, 1994; Sano et al, 1995) purpose, samples collected patients affected acute                                                       contributes CRC progression malignancy mechan-
ulcerative colitis, supposed characterised COX-2 protein                                                     isms act cell proliferation/invasion (Yamauchi et al, 2002;
expression. Levels COX-2 protein, COX-2 mRNA siCOX-2                                                           Strillacci et al, 2006), apoptosis inhibition (Tsujii DuBois,

& 2010 Cancer Research UK                                                                                                                             British Journal Cancer (2010) 103(7), 975 â€“ 986
                                                                           RNAi COX-2 silencing CRC cells
                                                                                                  Strillacci et al
                             982
                                                                                                                   HT-29                                                                               HT-29
                                                                                    350                                                                                       100
                                                                                    300       pS(â€“)
                                                                                                                                                                                  90




                                                               Cell number (x103)
                                                                                              pS(shCOX2)
                                                                                    250




                                                                                                                                                              Viability ( )
                                                                                              pS(â€“) INF                                                                                                                    pS(â€“)
                                                                                                                                                                                  80
                                                                                                                                                                                                                           pS(shCOX2)
                                                                                    200       pS(shCOX2) INF
                                                                                                                                                                                                                           pS(â€“) INF
                                                                                                                                                                                  70
                                                                                    150                                                                                                            *                       pS(shCOX2) INF
                                                                                                                                                                                  60                                   *
                                                                                    100                                                                                                                        *
                                                                                                                                                                                                                   *
                                                                                    50                                                                                            50
                                                                                                                                *           *         *
                                                                                     0                                                                                            40
                                                                                          0           1               2                 3         4                                     0       1           2      3   4
                                                                                                                     Days                                                                                  Days

                                                                                                                                                      HT-29 InvColi-infected
                                                                                                                                                        Days
                                                                                                                                                0 1 2 3 4 0 1 2                                 3 4
                                                                                                              COX-2 72 kDa

                                                                                                              -actin 42 kDa

                                                                                                                                                 HT-29-pSâ€“                        HT-29-pSshCOX-2
Translational Therapeutics




                                                                                                                                3.5
                                                                                                                                    3                                                  pS(â€“) INF
                                                                                                          relative expression




                                                                                                                                                                                       pS(shCOX2) INF
                                                                                                             COX-2/-actin




                                                                                                                                2.5
                                                                                                                                    2
                                                                                                                                1.5
                                                                                                                                                          *
                                                                                                                                    1                                         *
                                                                                                                                0.5         *                                               *
                                                                                                                                                                                                           *
                                                                                                                                    0
                                                                                                                                        0          1           2                        3              4
                                                                                                                                                              Days

                                   Figure 7 HT-29 cell survival bacterial infection depends COX-2 overexpression.   Cell number, (B) cell viability (C) COX-2 protein
                                   expression evaluated HT-29pS() HT-29pS(shCOX2) cells infected InvColi-pS (MOI 1:100), comparison control cells  infected).
                                   â€˜Materials Methodsâ€™ section details cell lines. (E) HT-29pS() cells, transduced pS() negative control vector; (â€™) HT-29pS(shCOX2)
                                   cells, transduced pS(shCOX2) vector stably silenced COX-2 protein; (m): HT-29pS() INF cells, transduced pS() negative control vector
                                   infected InvColi-pS; (K): HT-29pS(shCOX2) INF cells, transduced pS(shCOX2) vector infected InvColi-pS. Viability detected
                                   using Trypan Blue exclusion assay quantified ((number unstained cells)/(number total cells))  100. COX-2 protein expression
                                   evaluated western blot normalised b-actin protein. COX-2 relative expression refers infected HT-29pS() sample, day 0. Data
                                   represent meanÂ±s.e.m. independent experiments. *Po0.01.



                                   1995) tumour angiogenesis (Spisni Tomasi, 1997; iguez                                                                   (pSUPER.retro, pS). bacteria able infect/invade
                                   et al, 2003). demonstrated chronic use                                                                     CRC cells release DNA contents, leading strong
                                   NSAIDs, inhibitors COX activity, reduces CRC incidence                                                                       COX-2 silencing.
                                   treated patients (Phillips et al, 2002; Thun et al, 2002; Higuchi et al,                                                               modified pS vector gain tumour-specific
                                   2003; Sandler et al, 2003).  â€˜coxibsâ€™                                                                        shCOX-2 expression. basic pS vector allows constitutive
                                   developed marketed selective block COX-2 activity.                                                                  expression shCOX-2 (siCOX-2 precursor)                                    Celecoxib, rofecoxib, lumiracoxib etoricoxib em-                                                                     human cell line shCOX-2 transcription driven H1
                                   ployed clinical trials test safety associated                                                            promoter RNA pol III (pSH1).  modified                                    chronic use, data collected debated. high incidence                                                                 expression cassette substituting H1 promoter                                    cardiovascular adverse events associated chronic use                                                                human Cox-2 promoter  pSCOX2) promoter sequence
                                   coxibs (Bresalier et al, 2005; Solomon et al, 2005) clear                                                             containing TBEs  pSTBE), represent downstream
                                   pharmacological strategies, based COX-2 inhibition,                                                                  target sequences human genomic DNA Wnt/b-catenin-
                                   required prevention treatment CRC.                                                                           activated pathway. known Cox-2 promoter activity                                       Cyclooxygenase efficiently selectively inhibited                                                                  highly stimulated CRC cells. cellular stimuli contribute                                    RNAi techniques, transient long-lasting manner                                                                    activate phenomenon leads COX-2 overexpression
                                   (Strillacci et al, 2006). RNAi choice gene                                                                (Yamamoto et al, 1995; Dixon et al, 2001; Duque et al, 2005;
                                   silencing vitro despite disadvantages RNAi approaches                                                                   Wu et al, 2005; Kaidi et al, 2006; Strillacci et al, 2009). Wnt/b-
                                   vivo. RNAi-based silencing molecules delivered vivo                                                                   catenin pathway highly activated CRC cells                                    intravenous injections expressed use viral-based                                                                   activation caused cellular stimuli mutation proteins
                                   systems.  poor pharmacodynamics heavy                                                                          involved pathway, APC b-catenin itself
                                   effects reduce use effectiveness vivo.                                                                                (Morin et al, 1997; Brabletz et al, 2001, 2005; Castellone et al,
                                       provide data supporting alternative approach                                                                   2005). use pSCOX2 pSTBE vectors, demonstrated
                                   target CRC cells induce highly selective COX-2 silencing,                                                                    siCOX-2 expressed effective selective
                                   mediated RNAi, vitro ex vivo. particular,                                                                        manner CRC cells. Cox-2 TBE-based promoter
                                   engineered invasive E. coli strains (InvColi) carrying siCOX-2                                                                  control, siCOX-2 expression CRC cell lines (HT-29 HCA-7)
                                   (siRNA sequences targeting COX-2 mRNA)-expressing vectors                                                                          higher, compared H1-driven expression. 
                                   British Journal Cancer (2010) 103(7), 975 â€“ 986                                                                                                                                                   & 2010 Cancer Research UK
                                                                                                                               RNAi COX-2 silencing CRC cells
                                                                                                                              Strillacci et al
                                                                                                                                                                                                                                    983
                                                                            HCT-116                                                                                           HCT-116
                                                  500                                                                                      120
                                                  450       NI
                                                  400                                                                                      100




                             Cell number (x103)
                                                            pS(â€“)
                                                  350       pS(H1)




                                                                                                                           Viability ( )
                                                                                                                                            80
                                                  300       pS(COX2)
                                                                                                                                                                          *
                                                            pS(TBE)
                                                  250                                                                                      60
                                                  200                                                                                                    NI
                                                                                                                                           40            pS(â€“)
                                                                                                                                                                                 *      *       *
                                                  150
                                                                                                                                                         pS(H1)
                                                  100
                                                                                                                                           20            pS(COX2)
                                                   50                   *                             *
                                                                                                              *    *                                     pS(TBE)
                                                    0                                                                                        0
                                                        0           2                4                        6    8                                 0                2         4       6      8
                                                                                    Days                                                                                       Days
                                                                                                                         HCT-116
                                                                                                      1.2

                                                                            Relative invasion index       1

                                                                                                      0.8

                                                                                                      0.6




                                                                                                                                                                                                                                          Translational Therapeutics
                                                                                                      0.4
                                                                                                                    *              *             *                *
                                                                                                      0.2

                                                                                                          0
                                                                                                              NI   pSâ€“    pSH1 pSCOX-2 pSTBE

                                                                                                                                           InvColi

Figure 8 InvColi-pS infection impairs proliferation, viability invasiveness HCT-116 cells.   Cell number, (B) cell viability (C) invasiveness evaluated HCT-116 cells infected InvColi-pS strains (MOI 1:100). Viability evaluated using Trypan Blue exclusion assay quantified ((number unstained cells)/(number total cells))  100. (E): cells infected, NI; (â€™): cells infected InvColi-pS; (m): cells infected InvColi-
pSH1; (K): cells infected InvColi-pSCOX2; (*): cells infected InvColi-pSTBE. invasion assay performed using Boyden chambers 8-mm
polycarbonate membranes coated Matrigel (40-fold dilution). Relative invasion index refers HCT-116 cells infected (NI). Data represent
meanÂ±s.e.m. independent experiments. *Po0.01.


contrary, siCOX-2 resulted low expression normal colon                                                             infection effect InvColi-pSH1, InvColi-pSCOX2 epithelial cells (NCM-460) human tumour cell lines                                                                InvColi-pSTBE infection.  HT-29pS(shCOX2),  HeLa HEK-293).                                                                                                   biological effect HCT-116 cells dependent InvColi-pS
   Second, demonstrated shCOX-2-expressing vectors                                                                    infection se, siCOX-2 expression. (pSH1, pSCOX2 pSTBE) efficiently delivered                                                                   hand, global effect InvColi-pS infection CRC cell lines
HT-29 HCA-7 CRC cell lines infection InvColi                                                                   expressing COX-2 (HCA-7 HT-29) result COX-2
strains (MOI 1:1000), promoting strong COX-2                                                                      silencing mediated RNAi, PGE2 levels reduction cellular
regulation  mRNA protein levels) mediated RNAi                                                                 stress induced bacteria infection. prolonged reduction PGE2 levels. likely,                                                                      Finally, light possible vivo application, tested
phenomenon led significant reduction cell proliferation,                                                            ex vivo efficacy selective COX-2 silencing mediated InvColi-
viability invasiveness observed infected CRC cells.                                                               based RNAi. Colon tissue samples, derived patients affected interestingly, shCOX-2 expression driven TBE promoter                                                                  acute ulcerative colitis expressing COX-2 protein, infected
induced highest COX-2 silencing, resulted strong                                                               InvColi-pS strains resulted strong COX-2
impairment tumour-associated phenotype. clear                                                                 inhibition mRNA protein levels, especially infection  using pSTBE vector, possible gain efficacy                                                         InvColi-pSTBE. Cyclooxygenase-2 silencing associated specificity COX-2 silencing CRC cells.                                                                             significant reduction PGE2 pro-inflammatory/
   used model demonstrate pivotal role                                                               pro-angiogenic factors (cytokines, growth factors) released colon
COX-2 overexpression CRC cell survival. infecting HT-29                                                                 InvColi-pSTBE-infected cells.  observed increased
cells stably silenced COX-2 (HT-29pS(shCOX2), previously                                                                 production factors anti-inflammatory anti-tumour effects.
developed laboratory) InvColi-pS higher MOI                                                                    conclusion, developed RNAi-based strategy value (1:100), observed significant reduction cell                                                                    efficiently specifically silence COX-2 protein CRC cells,
proliferation survival, respect negative control                                                              vitro ex vivo. Cyclooxygenase-2 downregulation, depending
(HT-29pS() cells). known bacterial LPS induces                                                            InvColi-pS infection, induced strong impairment COX-2 expression human cells   InvColi-                                                              proliferative invasive behaviour CRC cells vitro pS infection MOI 1:100 induces COX-2 overexpression                                                                 significant anti-inflammatory anti-tumour effect ex vivo.
CRC cells, hypothesis survival CRC cells                                                             Taken  data demonstrate feasibility RNAi-
bacterial infection strictly dependent COX-2 induc-                                                               based/InvColi-driven approach COX-2 silencing aimed tion. observation confirmed HCT-116 cells,                                                              prevention CRC treatment inflammatory bowel
CRC cell line unable express COX-2. fact, lack COX-2                                                             diseases characterised COX-2 overexpression. Using engineered
protein induction InvColi-pS strain infection led                                                                  E. coli strains non-pathogenic bacteria, siCOX-2 silencing
significant impairment cell proliferation, viability invasive-                                                         locally delivered expressed colorectal tissues, ness HCT-116 cells. did record differences                                                              promoting blockade COX-2 activity, supposedly deprived InvColi-pS strains used HCT-116 infection. InvColi-pS                                                               systemic effects.

& 2010 Cancer Research UK                                                                                                                                                      British Journal Cancer (2010) 103(7), 975 â€“ 986
                                                                     RNAi COX-2 silencing CRC cells
                                                                                            Strillacci et al
                             984
                                                                                                                                    InvColi
                                                                                                                        â€“
                                                                                                             NC     pS          pSH1 pSCOX-2 pSTBE
                                                                                                                                                                                                  2
                                                                                           COX-2 72 kDa
                                                                                                                                                                                                1.8
                                                                                                                                                                                                1.6
                                                                                           -actin 42 kDa




                                                                                                                                                                            PGE2 log (pg ml )
                                                                                                                                                                           â€“1
                                                                                                                                                                                                1.4
                                                                                     1.2                                                                                                        1.2
                                                                                                                        COX-2 protein
                                                                                                                                                                                                  1                                   *
                                                                                                                                                               *
                                                               Relative expression    1                                 COX-2 mRNA
                                                                                                                        siCOX-2                                                                 0.8
                                                                                     0.8                                    *
                                                                                                                                           *                                                    0.6
                                                                                     0.6                                                                                                        0.4
                                                                                                                                     * *                                                        0.2
                                                                                     0.4
                                                                                                                        *                                                                         0
                                                                                     0.2                            *
                                                                                                                                                       *                                                            pSâ€“             pSTBE
                                                                                                                                                   *
                                                                                      0
                                                                                                                                                                                                                          InvColi
                                                                                              NC       pSâ€“         pSH1          pSCOX-2 pSTBE

                                                                                                                            InvColi

                                                                                                                  1
                                                                                                                                               *
Translational Therapeutics




                                                                                                                  1
                                                                                                                                                                                                *
                                                                                                                  1ra
                                                                                                                                                           *
                                                                                                                    2                                                                                        â€“
                                                                                                                                                            *                                       InvColi-pS
                                                                                                                    6                                                                            InvColi-pSTBE
                                                                                                                                                   *
                                                                                                                    7
                                                                                                                    8
                                                                                                                                                                                                      *
                                                                                                                    9
                                                                                                            12(p70)
                                                                                                                                                                           *
                                                                                                                  13
                                                                                                                  15
                                                                                                                                                   *
                                                                                                                  17
                                                                                                                                           *
                                                                                                            PDGF-bb
                                                                                                                                *
                                                                                                                  bFGF
                                                                                                                                                                       *
                                                                                                               G-CSF
                                                                                                             GM-CSF
                                                                                                                  VEGF
                                                                                                                                                                                                *
                                                                                                                  TNF
                                                                                                                                                           *
                                                                                                                   IFN
                                                                                                                  IP-10
                                                                                                                                                                   *
                                                                                                              Eotaxin                                                       *
                                                                                                               MCP-1
                                                                                                                                                                                                            *
                                                                                                              MIP-1
                                                                                                               MIP-1
                                                                                                                                                                                           *
                                                                                                               Rantes
                                                                                                                            1                      10            100                                                 1000
                                                                                                                                                               â€“1
                                                                                                                                                     Log (pg ml )

                                   Figure 9 InvColi-pS strains infect colon tissue samples induce high COX-2 silencing associated anti-inflammatory anti-angiogenic effects.
                                     COX-2 protein, COX-2 mRNA siCOX-2 levels analysed colon tissue samples western blot real-time PCR, 48 h InvColi strain
                                   infection. COX-2 protein, COX-2 mRNA siCOX-2 expression normalised b-actin protein, GUSB (b-glucuronidase) mRNA U6 RNA
                                   levels, respectively. Relative expression COX-2 protein COX-2 mRNA refers infected samples (negative control, NC); relative expression                                    siCOX-2 refers InvColi-pSTBE infected samples. Data represent meanÂ±s.e.m. independent experiments. *Po0.01. (B) Levels PGE2,
                                   (C) cytokines, chemokines growth factors quantified InvColi-pS- InvColi-pSTBE-infected colon tissues conditioned media, 48 h                                    infection, Luminex-based multiplexed bead immunoassay. Concentration values expressed log(pg ml1) represent meanÂ±CV                                    independent measurements, normalised considering total protein extracted tissue sample. *Po0.01.




                                   ACKNOWLEDGEMENTS                                                                                                                plasmid Dr Hans Clevers (University Hospital, Utrecht,                                                                                                                                                                    Netherlands) providing TOPFLASH plasmid.
                                   work supported grants MIUR (FIRB 2003
                                   RBNE03FMCJ VT PRIN 2008MT34AP ES). thank
                                   Dr Catherine Grillot-Courvalin (UniteÂ´ des Agents AntibacteÂ´riens,                                                              Supplementary Information accompanies paper British
                                   Institut Pasteur, Paris) providing pGB2-O-inv-hly                                                                        Journal Cancer website (http://www.nature.com/bjc)

                                   British Journal Cancer (2010) 103(7), 975 â€“ 986                                                                                                                                                       & 2010 Cancer Research UK
                                                                                 RNAi COX-2 silencing CRC cells
                                                                                Strillacci et al
                                                                                                                                                                  985
REFERENCES
Becker C, Fantini MC, Wirtz S, Nikolaev  Lehr HA, Galle PR, Rose-John S,      Hla T, Neilson K (1992) Human cyclooxygenase-2 cDNA. Proc Natl Acad
  Neurath MF (2005) 6 signaling promotes tumor growth colorectal             Sci USA 89: 7384 â€“ 7388
  cancer. Cell Cycle 4: 217 â€“ 220                                               Hsu S, Huang F, Friedman E (1995) Platelet-derived growth factor-B
Brabletz T, Hlubek F, Spaderna S, Schmalhofer O, Hiendlmeyer E, Jung             increases colon cancer cell growth vivo paracrine effect. J Cell
  Kirchner T (2005) Invasion metastasis colorectal cancer:                  Physiol 165: 239 â€“ 245
  epithelial-mesenchymal transition, mesenchymal-epithelial transition,         iguez MA, Rodriguez  Volpert OV, Fresno M, Redondo JM (2003)
  stem cells beta-catenin. Cells Tissues Organs 179: 56 â€“ 65                   Cyclooxygenase-2: therapeutic target angiogenesis. Trends Mol Med
Brabletz T, Jung  Reu S, Porzner M, Hlubek F, Kunz-Schughart LA,                 9: 73 â€“ 78
  Knuechel R, Kirchner T (2001) Variable beta-catenin expression             Kaidi  Qualtrough D, Williams AC, Paraskeva C (2006) Direct
  colorectal cancers indicates tumor progression driven tumor               transcriptional regulation cyclooxygenase-2 hypoxia-inducible
  environment. Proc Natl Acad Sci USA 98: 10356 â€“ 10361                            factor (HIF)-1 promotes colorectal tumor cell survival enhances
Bresalier RS, Sandler RS, Quan H, Bolognese JA, Oxenius B, Horgan K,               HIF-1 transcriptional activity hypoxia. Cancer Res 66: 6683 â€“ 6691
  Lines C, Riddell R, Morton D, Lanas  Konstam MA, Baron JA,                  Konishi N, Miki C, Yoshida T, Tanaka K, Toiyama Y, Kusunoki M (2005)
  Adenomatous Polyp Prevention Vioxx (APPROVe) Trial Investigators              Interleukin-1 receptor antagonist inhibits expression vascular
  (2005) Cardiovascular events associated rofecoxib colorectal           endothelial growth factor colorectal carcinoma. Oncology 68: 138 â€“ 145
  adenoma chemoprevention trial. N Engl J Med 352: 1092 â€“ 1102                  Koshiji M, Adachi Y, Sogo S, Taketani S, Oyaizu N, S, Inaba M, Phawa
Brew R, Erikson JS, West DC, Kinsella AR, Slavin J, Christmas SE (2000)            S, Hioki K, Ikehara S (1998) Apoptosis colorectal adenocarcinoma
  Interleukin-8 autocrine growth factor human colon carcinoma            (COLO 201) tumour necrosis factor-alpha (TNF-alpha)   cells vitro. Cytokine 12: 78 â€“ 85                                             interferon-gamma (IFN-gamma), resulting modulation Brummelkamp TR, Bernards R, Agami R (2002) Stable suppression                   Bcl-2 expression. Clin Exp Immunol 111: 211 â€“ 218
                                                                                Lewis DL, Hagstrom JE, Loomis AG, Wolff JA, Herweijer H (2002) Efficient




                                                                                                                                                                        Translational Therapeutics
  tumorigenicity virus-mediated RNA interference. Cancer Cell 2: 243 â€“ 247
Caporale  Brescia  Galati G, Castelli M, Saputo S, Terrenato  Cucina       delivery siRNA inhibition gene expression postnatal mice.
  Liverani  Gasparrini M, Ciardi  Scarpini M, Cosenza UM (2007)                Nat Genet 32: 107 â€“ 108
  Locoregional 2 therapy treatment colon cancer. Cell-induced      Liu W, Reinmuth N, Stoeltzing O, Parikh AA, Tellez C, Williams S, Jung YD,
  lesions murine model. Anticancer Res 27: 985 â€“ 989                          Fan F, Takeda  Akagi M, Bar-Eli M, Gallick GE, Ellis LM (2003)
Castagliuolo  Beggiao E, Brun P, Barzon L, Goussard S, Manganelli R,             Cyclooxygenase-2 regulated interleukin-1 beta human colorectal
  Grillot-Courvalin C, Palu` G (2005) Engineered E. coli delivers therapeutic      cancer cells multiple signaling pathways. Cancer Res 63: 3632 â€“ 3636
  genes colonic mucosa. Gene Ther 12: 1070 â€“ 1078                        Matsuo Y, Sawai H, Ma J, Xu D, Ochi N, Yasuda  Takahashi H, Funahashi
Castellone MD, Teramoto H, Williams BO, Druey KM, Gutkind JS (2005)                H, Takeyama H (2009) 1alpha secreted colon cancer cells enhances
  Prostaglandin E2 promotes colon cancer cell growth Gs-axin-            angiogenesis: relationship 1alpha release tumor cellsâ€™
  beta-catenin signaling axis. Science 310: 1504 â€“ 1510                            potential liver metastasis. J Surg Oncol 99: 361 â€“ 367
Chen C, Ridzon DA, Broomer AJ, Zhou  Lee DH, Nguyen JT, Barbisin M,           Morin PJ, Sparks AB, Korinek V, Barker N, Clevers H, Vogelstein B, Kinzler
  Xu NL, Mahuvakar VR, Andersen MR, Lao KQ, Livak KJ, Guegler KJ                   KW (1997) Activation beta-catenin-Tcf signaling colon cancer   (2005) Real-time quantification microRNAs stem-loop RT-PCR.                mutations beta-catenin APC. Science 275: 1787 â€“ 1790
  Nucleic Acids Res 33: e179                                                    Moyer MP, Manzano LA, Merriman RL, Stauffer JS, Tanzer LR (1996)
Crofford LJ, Wilder RL, RistimaÂ¨ki AP, Sano H, Remmers EF, Epps HR,                NCM460, anormal human colon mucosal epithelial cell line. Vitro Cell
  Hla T (1994) Cyclooxygenase-1 -2 expression rheumatoid synovial           Dev Biol Anim 32: 315 â€“ 317
  tissues. Effects interleukin-1 beta, phorbol ester, corticosteroids.   Oshima M, Dinchuk JE, Kargman SL, Oshima H, Hancock B, Kwong E,
  J Clin Invest 93: 1095 â€“ 1101                                                    Trzaskos JM, Evans JF, Taketo MM (1996) Suppression intestinal
Dixon DA, Tolley ND, King PH, Nabors LB, McIntyre TM, Zimmerman GA,                polyposis Apc delta716 knockout mice inhibition cyclooxygen-
  Prescott SM (2001) Altered expression mRNA stability factor HuR           ase 2 (COX-2). Cell 87: 803 â€“ 809
  promotes cyclooxygenase-2 expression colon cancer cells. J Clin Invest     Phillips RK, Wallace MH, Lynch PM, Hawk E, Gordon GB, Saunders BP,
  108: 1657 â€“ 1665                                                                 Wakabayashi N, Shen Y, Zimmerman S, Godio L, Rodrigues-Bigas M, Su
DuBois RN, Radhika  Reddy BS, Entingh AJ (1996) Increased                        LK, Sherman J, Kelloff G, Levin B, Steinbach G, FAP Study Group (2002)
  cyclooxygenase-2 levels carcinogen-induced rat colonic tumors.                randomized, 